Will This New Orphan Drug Go the Distance?

Endocyte (Nasdaq: ECYT  ) has partnered with pharma powerhouse Merck (NYSE: MRK  ) to develop its experimental drug vintafolide, a compound with orphan drug status in Europe that's used to treat a specific type of ovarian cancer. The companies submitted their official application for the approval of vintafolide to the European Medicines Agency (EMA) today.

As this drug goes under review, health-care analysts Max Macaluso and Brenton Flynn discuss the details of this partnership and another cancer drug for which Merck is seeking approval along with biotech Ariad (Nasdaq: ARIA  ) .

For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. Will Merck crumble under its own weight, or will it continue to pay dividends to investors for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand-new premium research report today. Our senior biotech analyst, Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2129546, ~/Articles/ArticleHandler.aspx, 10/26/2014 5:34:15 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 16,805.41 127.51 0.76%
S&P 500 1,964.58 13.76 0.71%
NASD 4,483.72 30.92 0.69%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2014 4:01 PM
MRK $57.61 Up +0.98 +1.73%
Merck & Co., Inc. CAPS Rating: ****
ARIA $5.83 Up +0.12 +2.10%
Ariad Pharmaceutic… CAPS Rating: ***
ECYT $5.81 Up +0.20 +3.57%
Endocyte, Inc. CAPS Rating: ***

Advertisement